메뉴 건너뛰기




Volumn 9, Issue 3, 2011, Pages 423-427

Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment

Author keywords

Clinical trial guidelines; Factor VIII; Factor VIII inhibitors; Hemophilia A

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING INHIBITOR; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

EID: 79952066899     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04169.x     Document Type: Review
Times cited : (18)

References (25)
  • 2
    • 0027392864 scopus 로고
    • A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
    • Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
    • (1993) Thromb Haemost , vol.69 , pp. 115-8
    • Peerlinck, K.1    Arnout, J.2    Gilles, J.G.3    Saint-Remy, J.M.4    Vermylen, J.5
  • 4
    • 67649855138 scopus 로고    scopus 로고
    • Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII
    • Recht M, Nemes L, Matysiak M, Manco-Johnson M, Lusher J, Smith M, Mannucci P, Hay C, Abshire T, O'Brien A, Hayward B, Udata C, Roth DA, Arkin S. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15: 869-80.
    • (2009) Haemophilia , vol.15 , pp. 869-80
    • Recht, M.1    Nemes, L.2    Matysiak, M.3    Manco-Johnson, M.4    Lusher, J.5    Smith, M.6    Mannucci, P.7    Hay, C.8    Abshire, T.9    O'Brien, A.10    Hayward, B.11    Udata, C.12    Roth, D.A.13    Arkin, S.14
  • 5
    • 37749022016 scopus 로고    scopus 로고
    • Report of Expert Meeting on Factor VIII Products and Inhibitor Development
    • European Medicines Agency. London: European Medicines Agency.
    • European Medicines Agency. Report of Expert Meeting on Factor VIII Products and Inhibitor Development. London: European Medicines Agency, 2007.
    • (2007)
  • 6
    • 79952044013 scopus 로고    scopus 로고
    • Office for Biologics Evaluation and Research and Office of Blood Research and Review and the International Association for Biologicals. The Factor VIII Inhibitor Workshop
    • US Food and Drug Administration (FDA). Bethesda, MD: US Food and Drug Administration (FDA).
    • US Food and Drug Administration (FDA). Office for Biologics Evaluation and Research and Office of Blood Research and Review and the International Association for Biologicals. The Factor VIII Inhibitor Workshop. Bethesda, MD: US Food and Drug Administration (FDA), 2003.
    • (2003)
  • 7
    • 0038383605 scopus 로고    scopus 로고
    • The epidemiology of inhibitors in haemophilia A: a systematic review
    • Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
    • (2003) Haemophilia , vol.9 , pp. 418-35
    • Wight, J.1    Paisley, S.2
  • 8
    • 0032973849 scopus 로고    scopus 로고
    • Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
    • White GC, DiMichele D, Mertens K, Negrier C, Peake IR, Prowse C, Schwaab R, Yoshioka A, Ingerslev J. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 462.
    • (1999) Thromb Haemost , vol.81 , pp. 462
    • White, G.C.1    DiMichele, D.2    Mertens, K.3    Negrier, C.4    Peake, I.R.5    Prowse, C.6    Schwaab, R.7    Yoshioka, A.8    Ingerslev, J.9
  • 12
    • 33751010515 scopus 로고    scopus 로고
    • Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development
    • Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006; 12: 102-6.
    • (2006) Haemophilia , vol.12 , pp. 102-6
    • Ettingshausen, C.E.1    Kreuz, W.2
  • 13
    • 77954506432 scopus 로고    scopus 로고
    • Rate of inhibitor development in previously-untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review
    • Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Mannucci PM, Nowak-Göttl U. Rate of inhibitor development in previously-untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review. J Thromb Haemost 2010; 8: 1256-65.
    • (2010) J Thromb Haemost , vol.8 , pp. 1256-65
    • Iorio, A.1    Halimeh, S.2    Holzhauer, S.3    Goldenberg, N.4    Marchesini, E.5    Marcucci, M.6    Young, G.7    Mannucci, P.M.8    Nowak-Göttl, U.9
  • 14
    • 79952056432 scopus 로고    scopus 로고
    • EMEA Public Statement. Review of recombinant factor VIII (FVIII) products and inhibitor development, Available at Accessed 17 May 2010.
    • EMEA Public Statement. Review of recombinant factor VIII (FVIII) products and inhibitor development, 2005. Available at Accessed 17 May 2010.
    • (2005)
  • 15
    • 13244281593 scopus 로고    scopus 로고
    • Hemophilia replacement products, clinical trials: inhibitors and pharmacokinetics-can they be done?
    • Aledort LM. Hemophilia replacement products, clinical trials: inhibitors and pharmacokinetics-can they be done? J Thromb Haemost 2004; 2: 1855-6.
    • (2004) J Thromb Haemost , vol.2 , pp. 1855-6
    • Aledort, L.M.1
  • 16
    • 0347662157 scopus 로고    scopus 로고
    • Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy
    • Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-48.
    • (1998) Transfus Sci , vol.19 , pp. 139-48
    • Giles, A.R.1    Rivard, G.E.2    Teitel, J.3    Walker, I.4
  • 17
    • 37149022850 scopus 로고    scopus 로고
    • Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers)
    • Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13: 65-8.
    • (2007) Haemophilia , vol.13 , pp. 65-8
    • Mannucci, P.M.1    Gringeri, A.2    Peyvandi, F.3    Santagostino, E.4
  • 18
    • 79952066105 scopus 로고    scopus 로고
    • Sippet Project. Survey of inhibitors in plasma-product exposed toddlers. Available at Accessed 15 October 2010.
    • Sippet Project. Survey of inhibitors in plasma-product exposed toddlers. Available at Accessed 15 October 2010.
  • 19
    • 44649131062 scopus 로고    scopus 로고
    • Performance of Bethesda assay and Nijmegen variant in external quality assessment (ECAT) of factor VIII inhibitor assays
    • Abstract O-T-093.
    • Verbruggen B, Meijer P. Performance of Bethesda assay and Nijmegen variant in external quality assessment (ECAT) of factor VIII inhibitor assays. J Thromb Haemost 2007;5(Suppl. 2): Abstract O-T-093.
    • (2007) J Thromb Haemost , vol.5 , Issue.SUPPL. 2
    • Verbruggen, B.1    Meijer, P.2
  • 20
    • 79952065974 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention. Universal Data Collection (UDC) Inhibitor Pilot Project Fact Sheet for HTC Providers. Available at Accessed 15 October 2010.
    • Centers for Disease Control and Prevention. Universal Data Collection (UDC) Inhibitor Pilot Project Fact Sheet for HTC Providers. Available at Accessed 15 October 2010.
  • 21
    • 0037330233 scopus 로고    scopus 로고
    • The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development
    • Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003; 29: 23-30.
    • (2003) Semin Thromb Hemost , vol.29 , pp. 23-30
    • Goodeve, A.C.1    Peake, I.R.2
  • 23
    • 13844276825 scopus 로고    scopus 로고
    • A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates
    • Lee ML, Roth DA. A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates. Haemophilia 2005; 11: 5-12.
    • (2005) Haemophilia , vol.11 , pp. 5-12
    • Lee, M.L.1    Roth, D.A.2
  • 25
    • 2342574192 scopus 로고    scopus 로고
    • FDA Workshop on factor VIII inhibitors held at the NIH, Bethesda, MA, on 21 November 2003
    • Ingerslev J. FDA Workshop on factor VIII inhibitors held at the NIH, Bethesda, MA, on 21 November 2003. Haemophilia 2004; 10: 288-9.
    • (2004) Haemophilia , vol.10 , pp. 288-9
    • Ingerslev, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.